RGEN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

116.750

Open

116.035

VWAP

116.25

Vol

178.72K

Mkt Cap

6.63B

Low

115.360

Amount

20.77M

EV/EBITDA(TTM)

43.41

Total Shares

56.33M

EV

6.40B

EV/OCF(TTM)

54.50

P/S(TTM)

9.01

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Show More

Events Timeline

(ET)

2026-02-24

07:40:00

Sees FY26 Revenue of $810M-$840M

2026-02-24

07:40:00

Repligen Reports Q4 Revenue of $197.913M, Exceeding Expectations

2026-01-30 (ET)

2026-01-30

10:50:00

Nvidia, Amazon, and Microsoft Plan to Invest Up to $60B in OpenAI

2026-01-06 (ET)

2026-01-06

07:40:00

Repligen Appoints Dr. Martin Madaus as Chair of the Board

2025-12-16 (ET)

2025-12-16

07:40:00

Repligen Launches Three New High-Performance Chromatography Resins

News

Fool

Brown Capital Management Sells AppFolio Shares Worth $45.11 Million

NASDAQ.COM

03-06NASDAQ.COM

Brown Capital Sells AppFolio Shares Worth $45.11 Million

seekingalpha

02-24seekingalpha

Repligen Corporation Reports Strong Q4 2025 Earnings and 2026 Guidance

seekingalpha

02-24seekingalpha

Repligen Q4 Earnings Exceed Expectations

Newsfilter

02-24Newsfilter

Repligen Exceeds 2025 Revenue Expectations with Strong Growth

seekingalpha

02-23seekingalpha

Repligen Scheduled to Announce Q4 Earnings on February 24

12 Analyst Rating

Wall Street analysts forecast RGEN stock price to rise

9 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

165.00

Averages

189.00

High

207.00

Current: 0.000

Low

165.00

Averages

189.00

High

207.00

Evercore ISI

Outperform -> NULL

downgrade

$180 -> $170

AI Analysis

2026-02-25

Reason

Evercore ISI

Price Target

$180 -> $170

AI Analysis

2026-02-25

downgrade

Outperform -> NULL

Reason

Evercore ISI lowered the firm's price target on Repligen to $170 from $180 and keeps an Outperform rating on the shares following the company's Q4 report and FY26 guidance.

UBS

Buy

downgrade

$200 -> $195

2026-02-25

Reason

UBS

Price Target

$200 -> $195

2026-02-25

downgrade

Buy

Reason

UBS lowered the firm's price target on Repligen to $195 from $200 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RGEN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Repligen Corp (RGEN.O) is 85.23, compared to its 5-year average forward P/E of 84.16. For a more detailed relative valuation and DCF analysis to assess Repligen Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

84.16

Current PE

85.23

Overvalued PE

103.70

Undervalued PE

64.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

56.81

Current EV/EBITDA

58.86

Overvalued EV/EBITDA

71.18

Undervalued EV/EBITDA

42.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

13.74

Current PS

11.59

Overvalued PS

16.94

Undervalued PS

10.53

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

so what Company is best for me

Intellectia · 79 candidates

Price: $5.00 - $400.00Relative Vol: >= 3List Exchange: XNYS, XNAS, XASEOne Week Rise Prob: >= 65One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Integer Holdings Corp

3.00B

Vertex Inc

2.12B

Charles Schwab Corp

164.81B

Sphere Entertainment Co

3.95B

Disc Medicine Inc

2.42B

Carter's Inc

1.55B

stocks that predict to rise in one week

Intellectia · 39 candidates

Market Cap: >= 5.00BPrice: $10.00 - $250.00One Week Rise Prob: >= 72One Week Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Cenovus Energy Inc

42.47B

Charles Schwab Corp

164.81B

NiSource Inc

22.11B

Atmos Energy Corp

30.06B

Colliers International Group Inc

5.69B

Repligen Corp

7.62B

Whales Holding RGEN

TimesSquare Capital Management, LLC

Stephens Investment Management Group, LLC

Perceptive Advisors LLC

Blue Whale Capital LLP

Vestal Point Capital, LP

Nationwide Fund Advisors

Trading Trends

People Also Watch

Frequently Asked Questions

What is Repligen Corp (RGEN) stock price today?

The current price of RGEN is 116.63 USD — it has decreased -0.83

What is Repligen Corp (RGEN)'s business?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

What is the price predicton of RGEN Stock?

Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is189.00 USD with a low forecast of 165.00 USD and a high forecast of 207.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Repligen Corp (RGEN)'s revenue for the last quarter?

Repligen Corp revenue for the last quarter amounts to 197.91M USD, increased 18.12

What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?

Repligen Corp. EPS for the last quarter amounts to 0.23 USD, decreased -138.33

How many employees does Repligen Corp (RGEN). have?

Repligen Corp (RGEN) has 2000 emplpoyees as of March 20 2026.

What is Repligen Corp (RGEN) market cap?

Today RGEN has the market capitalization of 6.63B USD.